The 3D echocardiography could provide early and detailed information about the changes in the left and right ventricle.
The prediction of sclerodermia associated pulmonary arterial hypertension (PAH) is rather adverse, so it makes sense to evaluate relevant changes of the left-ventricular longitudinal strain soon to adapt the PAH specific therapy accordingly.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age \>17
pulmonary arterial hypertension (PAH) associated with WHO group 1 who start a parenteral prostanoid-therapy
written informed consent
prostanoid naive
no change of the PAH specific therapy within 3 weeks of the recruitment to the study
You may not be if
pregnancy and lactation period
Women of child bearing potential who do not use an effective and secure method for birth control
severe chronic kidney insufficiency (glomerular filtration rate \<30), which will remain for more than 3 months
liver-insufficiency Child C
life expectancy shorter than the course of the study (for example because of malignant disease
Clareo Health | 3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH
